BBNX
Income statement / Annual
Last year (2024), Beta Bionics, Inc.'s total revenue was $65.12 M,
an increase of 442.93% from the previous year.
In 2024, Beta Bionics, Inc.'s net income was -$54.76 M.
See Beta Bionics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$65.12 M |
$12.00 M |
$179.00 K |
| Cost of Revenue |
$29.24 M
|
$5.69 M
|
$0.00
|
| Gross Profit |
$35.89 M
|
$6.31 M
|
$179.00 K
|
| Gross Profit Ratio |
0.55
|
0.53
|
1
|
| Research and Development Expenses |
$26.18 M
|
$17.94 M
|
$31.43 M
|
| General & Administrative Expenses |
$17.87 M
|
$12.23 M
|
$24.67 M
|
| Selling & Marketing Expenses |
$37.09 M
|
$11.99 M
|
$8.83 M
|
| Selling, General & Administrative Expenses |
$54.96 M
|
$24.22 M
|
$33.50 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.10 M
|
| Operating Expenses |
$81.14 M
|
$42.16 M
|
$66.02 M
|
| Cost And Expenses |
$110.38 M
|
$47.85 M
|
$66.02 M
|
| Interest Income |
$3.91 M
|
$1.78 M
|
$196.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$14.00 K
|
| Depreciation & Amortization |
$1.15 M
|
$1.23 M
|
$1.35 M
|
| EBITDA |
-$44.10 M |
-$34.62 M |
-$63.40 M |
| EBITDA Ratio |
-0.68
|
-2.89
|
-354.18
|
| Operating Income Ratio |
-0.69
|
-2.99
|
-367.84
|
| Total Other Income/Expenses Net |
-$9.51 M
|
-$8.25 M
|
$1.09 M
|
| Income Before Tax |
-$54.76 M
|
-$44.10 M
|
-$64.75 M
|
| Income Before Tax Ratio |
-0.84
|
-3.68
|
-361.74
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$54.76 M
|
-$44.10 M
|
-$64.75 M
|
| Net Income Ratio |
-0.84
|
-3.68
|
-361.74
|
| EPS |
-8.6 |
-8.31 |
-12.96 |
| EPS Diluted |
-8.6 |
-8.31 |
-12.96 |
| Weighted Average Shares Out |
$6.37 M
|
$5.30 M
|
$5.00 M
|
| Weighted Average Shares Out Diluted |
$6.37 M
|
$5.30 M
|
$5.00 M
|
| Link |
|
|
|
